Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Related Posts
Singh S, Youssef EG, Barbarino A, Hautau H, Nabeela S, Gebremariam T, Alkhazraji S, Ostroff G, Christensen D, Cochrane T, Ibrahim AS. Next-generation Candida albicans[...]
Tawakol A, Ribaudo H, McKhann A, Bellinge JW, Zureigat H, Fayad ZA, Lederman MM, Grinspoon SK, Kuritzkes DR, Stein JH, Ridker PM, Currier JS, Hsue[...]
Feelemyer J, Ban FK, Braithwaite RS, Bhattacharya D, Caniglia EC, Justice AC, Lim JK, Re VL, Scheidell J, Rentsch CT, Khan M. Associations Between Prior[...]